In this webinar we will discuss how the advancement of bioprocessing and the rise of novel treatment modalities such as viral vectors, as well as the urgent need for SARS-CoV-2 treatments and vaccines have driven the industry to adopt rapid alternatives. By illustrating the reasons behind the move to faster methods and discussing the wider benefits these can bring we hope to do our bit to drive change within this change resistant environment, and help our customers win the race to market.
In this webinar, you will get an overview about:
- Regulatory landscape and acceptance to alternate methods
- Considerations when looking to accelerate cell line characterization and lot release testing
- Overview of rapid technologies that are being accepted by the regulators for biosafety testing